Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial
Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Wei Chen(Xiamen University), Qi Liang(First Affiliated Hospital of Xi'an Jiaotong University), Shipo Wu(Academy of Military Medical Sciences), Abdul R Wurie(Ministry of Health and Sanitation), Lihua Hou(Zhejiang University), Manal Ghazzawi(Ministry of Health and Sanitation), Junzhi Wang(Hunan Academy of Agricultural Sciences), Qiang Guo, Yuemei Hu(Jiangsu Provincial Center for Disease Control and Prevention), Xu Zhang(University of Michigan), Zhe Zhang(Zhengzhou University), Wenjiao Yin(National Institute for Viral Disease Control and Prevention), Wen-Juan Wang(Chinese PLA General Hospital), Lei Duan(Northwest University), Wenbo Xu(Shenyang Institute of Automation), Jingxin Li(Beijing Tongren Hospital), Alie Wurie(Ministry of Health and Sanitation), Yuhua Li(Guangxi Medical University), James B. Russell(University of Sierra Leone)
Cited by 202
Related Papers
A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k